sarilumab - versus control - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.09 [0.56, 2.12]< 10%2 studies (2/-)39.5 %some concernnot evaluable moderatecrucial-
clinical improvement 1.03 [0.75, 1.41]> 10%1 study (1/-)57.4 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.09 [0.87, 1.35]> 10%2 studies (2/-)76.9 %some concernnot evaluable moderateimportant-

safety endpoints 00

serious adverse events 1.26 [0.82, 1.94]< 10%2 studies (2/-)14.4 %some concernnot evaluable moderateimportant-
adverse events 1.13 [0.77, 1.67]< 10%2 studies (2/-)26.9 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.